Stockscreener 앱 받기
1.72
9.47%
-0.18
시간 외 거래:
1.65
-0.07
-4.07%
전일 마감가:
$1.90
열려 있는:
$1.6
하루 거래량:
5.22M
Relative Volume:
2.65
시가총액:
$205.78M
수익:
$1.55M
순이익/손실:
$-63.06M
주가수익비율:
-2.1611
EPS:
-0.7959
순현금흐름:
$-49.45M
1주 성능:
-12.69%
1개월 성능:
-14.00%
6개월 성능:
-9.47%
1년 성능:
+44.54%
1일 변동 폭
$1.57
$1.89
1주일 범위
$1.57
$2.02
52주 변동 폭
$1.00
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
명칭
Milestone Pharmaceuticals Inc
전화
(514) 336-0444
주소
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.72 | 227.31M | 1.55M | -63.06M | -49.45M | -0.7959 |
VRTX
Vertex Pharmaceuticals Inc
|
453.06 | 113.78B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
719.88 | 75.84B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.70 | 50.55B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.48 | 38.99B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
316.55 | 32.69B | 5.76B | 514.49M | 1.10B | 4.4813 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Strong Buy |
| 2025-12-15 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-09-11 | 개시 | Wells Fargo | Overweight |
| 2025-06-05 | 재개 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2023-06-20 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-22 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | 개시 | H.C. Wainwright | Buy |
| 2020-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-07-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-03-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | 개시 | Oppenheimer | Outperform |
| 2019-06-03 | 개시 | Cowen | Outperform |
| 2019-06-03 | 개시 | Jefferies | Buy |
| 2019-06-03 | 개시 | Piper Jaffray | Overweight |
모두보기
Milestone Pharmaceuticals Inc 주식(MIST)의 최신 뉴스
Milestone Pharmaceuticals Files $300 Million Mixed Shelf - Moomoo
Milestone Pharmaceuticals Inc (MIST) Q1 2026 Earnings Call Highl - GuruFocus
Milestone Pharmaceuticals Inc. Stock 12‑Month Price Target Cut to $6.33, Implies 233% Upside - TradingView
Why Milestone Pharmaceuticals Stock Wilted on Wednesday - Yahoo Finance
According to documents submitted to the U.S. Securities and Exchange Commission (SEC), Milestone Pharmaceuticals Inc. may issue and sell common shares worth up to 100 million dollars through an equity distribution sales agreement with Cantor Fitzgeral - Bitget
Milestone Pharmaceuticals (NASDAQ: MIST) files $300M shelf; $100M ATM with Cantor Fitzgerald - Stock Titan
Q1 2026 Milestone Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Milestone Pharmaceuticals (MIST) Reports Q1 Earnings Miss - GuruFocus
Milestone Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Milestone Pharmaceuticals (MIST) Q1 2026 Earnings: EPS and Reven - GuruFocus
Milestone Pharmaceuticals Inc. Q1 2026 10-Q Report: Financial Statements, Risk Factors, and Forward-Looking Statements - Minichart
Milestone Pharmaceuticals (MIST) Reports Strong Q1 Revenue Growt - GuruFocus
Milestone Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Milestone Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Milestone Pharmaceuticals Q1 2026 misses forecasts, stock drops - Investing.com
Milestone Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript - Benzinga
Milestone Pharmaceuticals shares plunge after CARDAMYST revenue misses expectations (MIST) - Yahoo Finance
Adage (MIST) holds 8,000,000 warrant-derived shares, 6.37% - Stock Titan
Milestone Shares Fall on Unexpected 1Q Loss - Moomoo
Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Milestone Pharmaceuticals earnings missed by $0.43, revenue fell short of estimates - Investing.com Canada
Milestone Pharmaceuticals reports Q1 2026: $0.2M product revenue, $26.1M net loss, $184.2M cash - TradingView
Milestone Pharmaceuticals stock tumbles 16% on revenue miss By Investing.com - Investing.com Nigeria
Milestone Pharmaceuticals stock tumbles 16% on revenue miss - Investing.com UK
Canada's Milestone Pharmaceuticals Q1 revenue misses estimates after CARDAMYST launch - TradingView
Milestone Pharmaceuticals Reports Progress on CARDAMYST™ Launch and Financial Performance for Q1 2026 - Quiver Quantitative
Milestone Pharmaceuticals: Q1 Earnings Snapshot - standard-journal.com
Milestone Pharmaceuticals Inc. 1Q 2026: Revenue $0.24M, Net loss $26.07M, EPS $(0.20) — 10-Q Summary - TradingView
Milestone Pharmaceuticals (NASDAQ: MIST) posts first CARDAMYST sales and boosts cash with royalty deal - Stock Titan
TradingKey - TradingKey
Milestone Pharmaceuticals Inc expected to post earnings of 31 cents a shareEarnings Preview - TradingView
Earnings Preview: MIST to Report Financial Results Pre-market on May 13 - Moomoo
Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026 - The Manila Times
Biotech Milestone pairs May 13 results with investor webcast - Stock Titan
Milestone Pharmaceuticals gears up for Q4 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
[DEF 14A] Milestone Pharmaceuticals Inc. Definitive Proxy Statement - Stock Titan
[ARS] Milestone Pharmaceuticals Inc. SEC Filing - Stock Titan
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Update - MarketBeat
MIST stock soars pre-market after FDA approves first commercial product – retail remains bullish, dismisses 'sell the news' concerns - MSN
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Milestone (MIST) Business Update | Q4 2025: Below ExpectationsBlock Trade - Xã Thanh Hà
Milestone Pharmaceuticals (MIST) Proxy Filing Summary - Quartr
Insider Sell: Joseph Oliveto Sells 36,500 Shares of Milestone Ph - GuruFocus
Milestone (MIST) CEO sells 36,500 shares under Rule 10b5-1 plan - Stock Titan
Why Milestone Pharma stock is taking a dive today - MSN
[144] Milestone Pharmaceuticals Inc. SEC Filing - Stock Titan
RSI Check: What are the risks of holding Milestone Pharmaceuticals Inc2026 Final Week & Growth Focused Stock Pick Reports - baoquankhu1.vn
Risk Check: Is Milestone Pharmaceuticals Inc a momentum stock2026 Investor Takeaways & Real-Time Volume Spike Alerts - baoquankhu1.vn
MIST: CARDAMYST launches with strong clinical data, broad provider targeting, and robust financial runway - TradingView
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone - Yahoo Finance
Milestone Pharmaceuticals Inc (MIST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.58%
3.00%
자본화:
|
볼륨(24시간):